People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Pharmaceuticals, Biotech / Pharma, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Triana Biomedicines, Inc. | — | Pharmaceuticals | Series D+ | $178.6M | $852.8M | 2025 |
| Seismic Therapeutic, Inc. | — | Biotech / Pharma | Series D+ | $146.3M | $1.9B | 2023 |
| TScan Therapeutics, Inc. | — | Biotechnology | Series C | $123.3M | $3.3B | 2021 |
| RIMSYS Inc. | — | Other Health Care | Series B | $24.2M | $37.5M | 2021 |
| Nido Biosciences, Inc. | — | Biotech / Pharma | Series B | $22.4M | $637.1M | 2020 |
Andrew Hedin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Hedin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Shelley Chu | 2 | 10 |
| ANDREW LEVIN | 1 | 17 |
| Andrew Schwab | 1 | 16 |
| Joshua Resnick | 1 | 12 |
| Campbell Murray | 1 | 9 |
| Alan Crane | 1 | 9 |
| Christopher O'Donnell | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| John McIlwraith | 1 | 7 |
| Robert Crane | 1 | 7 |
| Ittai Harel | 1 | 6 |
| Timothy Barberich | 1 | 6 |
| David Grayzel | 1 | 6 |
| Steve Kraus | 1 | 6 |
| Lorence Kim | 1 | 5 |
| Milind Deshpande | 1 | 4 |
| Timothy A. Springer | 1 | 4 |
| Nandita Shangari | 1 | 4 |
| Jacqueline Grant | 1 | 3 |
| David Southwell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.